TWI868714B - 用於治療非小細胞肺癌之奧希替尼 - Google Patents

用於治療非小細胞肺癌之奧希替尼 Download PDF

Info

Publication number
TWI868714B
TWI868714B TW112120315A TW112120315A TWI868714B TW I868714 B TWI868714 B TW I868714B TW 112120315 A TW112120315 A TW 112120315A TW 112120315 A TW112120315 A TW 112120315A TW I868714 B TWI868714 B TW I868714B
Authority
TW
Taiwan
Prior art keywords
chemoradiotherapy
osimertinib
egfr
patients
platinum
Prior art date
Application number
TW112120315A
Other languages
English (en)
Chinese (zh)
Other versions
TW202412804A (zh
Inventor
安東尼 法蘭西斯 派翠克 納許
Original Assignee
瑞典商阿斯特捷利康公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 瑞典商阿斯特捷利康公司 filed Critical 瑞典商阿斯特捷利康公司
Publication of TW202412804A publication Critical patent/TW202412804A/zh
Application granted granted Critical
Publication of TWI868714B publication Critical patent/TWI868714B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW112120315A 2018-02-12 2019-02-11 用於治療非小細胞肺癌之奧希替尼 TWI868714B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862629166P 2018-02-12 2018-02-12
US62/629,166 2018-02-12

Publications (2)

Publication Number Publication Date
TW202412804A TW202412804A (zh) 2024-04-01
TWI868714B true TWI868714B (zh) 2025-01-01

Family

ID=65443828

Family Applications (2)

Application Number Title Priority Date Filing Date
TW112120315A TWI868714B (zh) 2018-02-12 2019-02-11 用於治療非小細胞肺癌之奧希替尼
TW108104348A TW201941773A (zh) 2018-02-12 2019-02-11 用於治療非小細胞肺癌之奧希替尼

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW108104348A TW201941773A (zh) 2018-02-12 2019-02-11 用於治療非小細胞肺癌之奧希替尼

Country Status (15)

Country Link
US (4) US20200368231A1 (https=)
EP (2) EP4431154A3 (https=)
JP (2) JP2021513517A (https=)
KR (2) KR20200119243A (https=)
CN (2) CN116870008A (https=)
AU (2) AU2019219304A1 (https=)
BR (1) BR112020015507A2 (https=)
CA (1) CA3090010A1 (https=)
EA (1) EA202091841A1 (https=)
IL (1) IL276406A (https=)
MA (1) MA51823A (https=)
MX (1) MX2020008395A (https=)
SG (1) SG11202007414XA (https=)
TW (2) TWI868714B (https=)
WO (1) WO2019155059A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3133766A1 (en) 2019-03-29 2020-10-08 Astrazeneca Ab Osimertinib for use in the treatment of non-small cell lung cancer
CN110433296A (zh) * 2019-08-16 2019-11-12 哈尔滨医科大学 一种19f-mr/荧光多模式分子成像及载药的诊疗一体化纳米探针及制备方法和应用
WO2021148396A1 (en) * 2020-01-20 2021-07-29 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
WO2022120197A1 (en) * 2020-12-03 2022-06-09 Emory University Combinations of epidermal growth factor receptor inhibitors and sterol regulatory element-binding protein inhibitors for uses in cancer therapies
WO2022166794A1 (zh) * 2021-02-02 2022-08-11 贝达药业股份有限公司 埃克替尼在非小细胞肺癌术后辅助治疗中的应用
US20240226101A1 (en) * 2021-04-30 2024-07-11 Suzhou Puhe BioPharma Co., Ltd. Pyrimidinylaminobenzenes for lung cancer treatment
CN114917231A (zh) * 2022-05-27 2022-08-19 杭州师范大学 β-榄香稀和奥希替尼药物组合在制备抗肺癌药物上的应用
KR102899565B1 (ko) 2023-02-14 2025-12-11 박주현 좁은 전시공간에서 전시품의 360도 실감 영상투사식 전시장치

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI583386B (zh) * 2011-07-27 2017-05-21 阿斯特捷利康公司 ２-（２，４，５-經取代苯胺基）嘧啶化合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201400034D0 (en) * 2014-01-02 2014-02-19 Astrazeneca Ab Pharmaceutical Compositions comprising AZD9291
EP3191523B1 (en) * 2014-09-08 2019-08-07 Yeda Research and Development Co., Ltd. Compositions and methods for treating cancer resistant to a tyrosine kinase inhibitor (tki)
WO2016164217A1 (en) * 2015-04-09 2016-10-13 Clovis Oncology, Inc. Therapeutic combinations for treating cancer
WO2017164887A1 (en) * 2016-03-25 2017-09-28 OSI Pharmaceuticals, LLC Pulse dosing regimen and methods for treatment
US10813933B2 (en) * 2016-05-17 2020-10-27 Japanese Foundation For Cancer Research Therapeutic agent for lung cancer that has acquired EGFR-TKI resistance
US20200038398A1 (en) * 2017-03-10 2020-02-06 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI583386B (zh) * 2011-07-27 2017-05-21 阿斯特捷利康公司 ２-（２，４，５-經取代苯胺基）嘧啶化合物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
期刊 Soria et al. Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer THE NEW ENGLAND JOURNAL OF MEDICINE 378 2018 113-125;期刊 Yoon et al. Therapeutic management options for stage III non-small cell lung cancer 3. WORLD JOURNAL OF CLINICAL ONCOLOGY 8(1) 2017 1-20 *
期刊 Yoon et al. Therapeutic management options for stage III non-small cell lung cancer 3. WORLD JOURNAL OF CLINICAL ONCOLOGY 8(1) 2017 1-20

Also Published As

Publication number Publication date
KR20200119243A (ko) 2020-10-19
JP2023116537A (ja) 2023-08-22
AU2022203007B2 (en) 2024-07-04
EA202091841A1 (ru) 2020-10-28
TW202412804A (zh) 2024-04-01
US20240156815A1 (en) 2024-05-16
WO2019155059A1 (en) 2019-08-15
SG11202007414XA (en) 2020-09-29
US20230226059A1 (en) 2023-07-20
AU2022203007A1 (en) 2022-05-26
CN111683663A (zh) 2020-09-18
EP3752153A1 (en) 2020-12-23
MA51823A (fr) 2021-05-19
KR20260009945A (ko) 2026-01-20
EP4431154A3 (en) 2024-12-11
US20220184076A1 (en) 2022-06-16
CA3090010A1 (en) 2019-08-15
MX2020008395A (es) 2020-09-21
BR112020015507A2 (pt) 2021-01-26
US20200368231A1 (en) 2020-11-26
JP2021513517A (ja) 2021-05-27
IL276406A (en) 2020-09-30
EP4431154A2 (en) 2024-09-18
TW201941773A (zh) 2019-11-01
CN116870008A (zh) 2023-10-13
AU2019219304A1 (en) 2020-09-24

Similar Documents

Publication Publication Date Title
TWI868714B (zh) 用於治療非小細胞肺癌之奧希替尼
Leonetti et al. Phase II, open-label, single-arm, multicenter study to assess the activity and safety of alectinib as neoadjuvant treatment in surgically resectable stage III ALK-positive NSCLC: ALNEO trial
JP6695003B2 (ja) 癌のための併用療法
Saba et al. Phase 1 and pharmacokinetic study of everolimus in combination with cetuximab and carboplatin for recurrent/metastatic squamous cell carcinoma of the head and neck
CN109310754A (zh) 使用包含抗erbb3抗体的联合疗法治疗er+、her2-、hrg+乳腺癌的方法
WO2024050396A1 (en) Methods of treating solid tumors having activating fgfr3 gene alterations
Spicer et al. A phase II study of neoadjuvant opnurasib KRAS G12C inhibitor in patients with surgically resectable non-small cell lung cancer (CCTG IND. 242A): A substudy of the IND. 242 platform master protocol
JP2023543261A5 (https=)
Cheng et al. Adaptation of international guidelines for metastatic colorectal cancer: an Asian consensus
Abdelwahab et al. Anti-EGFR (cetuximab) combined with irinotecan for treatment of elderly patients with metastatic colorectal cancer (mCRC)
HK40116781A (en) Osimertinib for use in the treatment of non-small cell lung cancer
Jänne et al. P1. 01-41 A Phase 2 Study of DS-8201a in HER2-Overexpressing or-Mutated Advanced Non-Small-Cell Lung Cancer
Zarkar et al. A study of pazopanib safety and efficacy in patients with advanced clear cell renal cell carcinoma and ECOG performance status 2 (Pazo2): an open label, multicentre, single arm, phase II trial
Trédaniel et al. Final results of the IFCT-0803 study, a phase II study of cetuximab, pemetrexed, cisplatin, and concurrent radiotherapy in patients with locally advanced, unresectable, stage III, non-squamous, non-small-cell lung cancer
US20250099580A1 (en) Treatment of gastric cancer and/or gastroesophageal junction cancer
Yang et al. HS-10296–a novel third generation EGFR tyrosine kinase inhibitor: results of the first-in-human phase 1 trial in patients with previously treated EGFR mutant advanced non-small-cell lung cancer
Galli THE EUDRACT 2017-004494-13 TRIAL ON THYMIC EPITHELIAL TUMORS: THE PARADIGM OF A COMPREHENSIVE STUDY FOR A RARE DISEASE
AU2024346588A1 (en) Treatment of gastric cancer and/or gastroesophageal junction cancer
Yao et al. FRESCO-2: a global Phase III study investigating the efficacy and safety of fruquintinib in metastatic colorectal cancer
CN120035437A (zh) 用于治疗EGFR突变癌症的N-(1-((R)-1-丙烯酰基氮杂环庚烷-3-基)-7-氯-6-(((R)-四氢呋喃-3-基)氧基)-1H-苯并[d]咪唑-2-基)-2-甲基异烟酰胺(NX-019)
Cheng et al. 173P: Vascular endothelial growth factor-C promotes EGFR-TKIs resistance and cancer stemness via SLUG of non-small cell lung cancer
Coucke A phase I trial of sunitinib, a tyrosine kinase inhibitor (TKI) combined with ionizing irradiation in rectal cancer
Coucke A dosimetric study comparing breast radiotherapy planned in the prone versus supine positions and via conformal 3D versus IMRT techniques
TW201703769A (zh) 用於癌症的組合療法